Send us Feedback

Dendreon (DNDN)
Analysis
SUMMARY
BULLS
BEARS
TOPICS
Data
DATA CENTRAL
STOCK CHART
Financials
SEC FILINGS
BALANCE
INCOME
CASH FLOW
QUOTE AND NEWS
Dendreon upbeat on ability to make Provenge next year
FierceBiotech  Jan 12  Comment 
Dendreon expects to reach full manufacturing capacity for experimental prostate cancer drug Provenge by mid-2011, and will immediately launch sales of the drug when it is approved by U.S. regulators, the company's CEO said at the J.P. Morgan...
Dendreon (DNDN) NewsBite - Roth Capital Starts DNDN at Buy
Market Intelligence Center  Jan 7  Comment 
Dendreon (NASDAQ: DNDN) opened at $29.99. So far today, the stock has hit a low of $29.85 and a high of $30.90. DNDN is now trading at $30.47, up $1.06 (3.6%). Over the last 52 weeks the stock has ranged from a low of $2.55 to a high of $30.42....
3 Reasons to Sell Dendreon Today
Motley Fool  Dec 18  Comment 
Not everyone is on the buy side.
(DNDN) Dendreon Corporation Prices Stock Offer
Stock Blog Hub  Dec 15  Comment 
Dendreon Corporation (DNDN) announced recently that it has priced its common stock at $24.75 per share in its public offering to sell 15 million shares of common stock. The offer is underwritten by JP Morgan Securities, a division of JP Morgan...
Dendreon (DNDN) NewsBite - DNDN Sinks on Stock Offering
Market Intelligence Center  Dec 11  Comment 
Dendreon (NASDAQ: DNDN) opened at $25.17. So far today, the stock has hit a low of $25.10 and a high of $25.57. DNDN is now trading at $25.30, down $0.35 (-1.36%). Over the last 52 weeks the stock has ranged from a low of $2.55 to a high of...
Dendreon (DNDN) Prices 15M Common Offering at $24.75/Share
StreetInsider.com  Dec 11  Comment 
Dendreon Announces Pricing of Common Stock Offering
PR Newswire  Dec 11  Comment 
Dendreon stays focused on launch countdown
FierceBiotech  Dec 11  Comment 
Dendreon may not have an approval yet for its prostate cancer therapy, but it's acting a lot like it's a done deal. In the last two days, Dendreon has raised $356 million from a stock sale and hired Bayer HealthCare veteran Hans Bishop as its COO....
Dendreon (DNDN) Hires Hans Bishop as COO
StreetInsider.com  Dec 11  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Management+Changes/Dendreon+%28DNDN%29+Hires+Hans+Bishop+as+COO/5176754.html for the full story.
Dendreon (DNDN) Names Hans Bishop COO
StreetInsider.com  Dec 10  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Management+Changes/Dendreon+%28DNDN%29+Names+Hans+Bishop+COO/5173251.html for the full story.
(DNDN) Dendreon Corporation Raising Money
Stock Blog Hub  Dec 9  Comment 
Dendreon Corporation (DNDN) announced recently that it will sell 15 million shares of common stock in a public offering underwritten by JP Morgan Securities, a division of JP Morgan Chase & Co (JPM) and Deutsche Bank (DB). The underwriters will...



Thank you for your suggestion
SEC FILINGS
SEC FILINGS  (See all)
10-K (Mar 09)
Older: 03/12/08, 04/13/07, 03/14/07, 03/15/06
10-Q (Nov 09)
Older: 08/10/09, 05/06/09, 11/10/08, 08/11/08
View All Filings for Dendreon (DNDN)
RELATED WIKI ARTICLES

Related Articles

more ▼WIKI ANALYSIS
 
DNDN AT A GLANCE
 
 
 
 
 
 
 
 

Dendreon Corporation (DNDN) is a biotechnology company with a focus on developing drugs for cancer. Its most advanced product is Provenge (Sipuleucel-T), a therapeutic vaccine candidate being developed for the treatment of prostate cancer. Provenge could have blockbuster potential if the ongoing clinical late-stage trial yields positive results. Dendreon will market Provenge in the U.S. on its own. And we expect Dendreon to announce a partner for Provenge in the rest of the world soon. Another important product under clinical development is APC-8024 (Lapuleucel-T, Neuvenge) for the treatment of breast, ovarian, and colorectal cancers. The company has no products on the market and derives its revenue entirely from collaborations with other companies. Based in Seattle, WA, the company employs nearly 150 people.




References

Retrieved from "http://www.wikinvest.com/stock/Dendreon_(DNDN)"
Wikinvest © 2006, 2007, 2008, 2009, 2010. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki